Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis.
Nanna B. Finnerup,Nadine Attal,Simon Haroutounian,Ewan D McNicol,Ralf Baron,Robert H. Dworkin,Ian Gilron,Maija Haanpää,Per Hansson,Per Hansson,Troels S. Jensen,Troels S. Jensen,Peter R. Kamerman,Karen Lund,Andrew Moore,Srinivasa N. Raja,Andrew S.C. Rice,Andrew S.C. Rice,Michael C. Rowbotham,Emily S. Sena,Emily S. Sena,Philip J. Siddall,Philip J. Siddall,Blair H. Smith,Mark S. Wallace +24 more
Reads0
Chats0
TLDR
The results support a revision of the NeuPSIG recommendations for the pharmacotherapy of neuropathic pain and allow a strong recommendation for use and proposal as first-line treatment in neuropathicPain for tricyclic antidepressants, serotonin-noradrenaline reuptake inhibitors, pregabalin, and gabapentin.Abstract:
Summary Background New drug treatments, clinical trials, and standards of quality for assessment of evidence justify an update of evidence-based recommendations for the pharmacological treatment of neuropathic pain. Using the Grading of Recommendations Assessment, Development, and E valuation (GRADE), we revised the Special Interest Group on Neuropathic Pain (NeuPSIG) recommendations for the pharmacotherapy of neuropathic pain based on the results of a systematic review and meta-analysis. Methods Between April, 2013, and January, 2014, NeuPSIG of the International Association for the Study of Pain did a systematic review and meta-analysis of randomised, double-blind studies of oral and topical pharmacotherapy for neuropathic pain, including studies published in peer-reviewed journals since January , 1966, and unpublished trials retrieved from ClinicalTrials.gov and websites of pharmaceutical companies. We used number needed to treat (NNT) for 50% pain relief as a primary measure and assessed publication bias; NNT was calculated with the fi xed-eff ects Mantel-Haenszel method. Findings 229 studies were included in the meta-analysis. Analysis of publication bias suggested a 10% overstatement of treatment eff ects. Studies published in peer-reviewed journals reported greater eff ects than did unpublished studies (r² 9·3%, p=0·009). T rial outcomes were generally modest: in particular, combined NNTs were 6·4 (95% CI 5·2–8·4) for serotonin-noradrenaline reuptake inhibitors, mainly including duloxetine (nine of 14 studies); 7·7 (6·5–9·4) for pregabalin; 7·2 (5·9–9·21) for gabapentin, including gabapentin extended release and enacarbil; and 10·6 (7·4–19·0) for capsaicin high-concentration patches. NNTs were lower for tricyclic antidepressants, strong opioids, tramadol, and botulinum toxin A, and undetermined for lidocaine patches. Based on GRADE, fi nal quality of evidence was moderate or high for all treatments apart from lidocaine patches; tolerability and safety, and values and preferences were higher for topical drugs; and cost was lower for tricyclic antidepressants and tramadol. These fi ndings permitted a strong recommendation for use and proposal as fi rst-line treatment in neuropathic pain for tricyclic antidepressants, serotonin-noradrenaline reuptake inhibitors, pregabalin, and gabapentin; a weak recommendation for use and proposal as second line for lidocaine patches, capsaicin high-concentration patches, and tramadol; and a weak recommendation for use and proposal as third line for strong opioids and botulinum toxin A. Topical agents and botulinum toxin A are recommended for peripheral neuropathic pain only. Interpretation Our results support a revision of the NeuPSIG recommendations for the pharmacotherapy of neuropathic pain. Inadequate response to drug treatments constitutes a substantial unmet need in patients with neuropathic pain. Modest effi cacy, large placebo responses, heterogeneous diagnostic criteria, and poor phenotypic profi ling probably account for moderate trial outcomes and should be taken into account in future studies. Funding NeuPSIG of the International Association for the Study of Pain.read more
Citations
More filters
Journal ArticleDOI
Gabapentin as add-on to morphine for severe neuropathic or mixed pain in children from age 3 months to 18 years - evaluation of the safety, pharmacokinetics, and efficacy of a new gabapentin liquid formulation: study protocol for a randomized controlled trial
Thomas G. de Leeuw,Laura Mangiarini,Rebecca Lundin,Florentia Kaguelidou,Florentia Kaguelidou,Tjitske M van der Zanden,Oscar Della Pasqua,Dick Tibboel,Adriana Ceci,Saskia N. de Wildt,Saskia N. de Wildt +10 more
TL;DR: The GAPP-2 study hopes to provide evidence that the combination of morphine and gabapentin will provide better analgesia than morphine alone and will be safe and obtain confirmation of the recommended pediatric dose.
Journal ArticleDOI
Unravelling the role of unmyelinated nerve fibres in trigeminal neuralgia with concomitant continuous pain
Gianfranco De Stefano,Caterina Leone,G. Di Pietro,N. Esposito,Pietro Falco,Eleonora Galosi,Daniel Litewczuk,Cristina Mollica,Andrea Truini,G. Di Stefano +9 more
TL;DR: In this paper , a clinical and neurophysiological study was conducted to test trigeminal nerve fibre function in patients with trigemial neuralgia, with and without concomitant continuous pain.
Journal ArticleDOI
A Delphi consensus statement of the Neuropathic Pain Special Interest Group of the Italian Neurological Society on pharmacoresistant neuropathic pain
Palma Ciaramitaro,Giorgio Cruccu,M. de Tommaso,Grazia Devigili,Diego Fornasari,Pierangelo Geppetti,Marco Lacerenza,Giuseppe Lauria,Giuseppe Lauria,S. Mameli,P. Marchettini,P. Marchettini,Maria Nolano,Enrico Polati,Vincenzo Provitera,Marcello Romano,Claudio Solaro,Stefano Tamburin,Valeria Tugnoli,Massimiliano Valeriani,Andrea Truini +20 more
TL;DR: A consensus statement is agreed that neuropathic pain is pharmacoresistant when the patient does not reach the 50% reduction of pain or an improvement of at least 2 points in the Patient Global Impression of Change, thus improving patient care and helping clinical research.
Journal ArticleDOI
Small-Fiber-Neuropathien
Claudia Sommer,Nurcan Üçeyler +1 more
TL;DR: Das klinische Bild der Small-Fiber-Neuropathie, einer Erkrankung der dunn bemarkten A-delta- und unbemarkten C-Fasern, ist gepragt durch brennende akrale Schmerzen.
Journal ArticleDOI
Inhibition of voltage-gated sodium channels by sumatriptan bioisosteres
Roberta Carbonara,Alessia Carocci,Julien Roussel,Giuseppe Crescenzo,Canio Buonavoglia,Carlo Franchini,Giovanni Lentini,Diana Conte Camerino,Jean-François Desaphy +8 more
TL;DR: This study evaluated whether sumatriptan and its congeners may inhibit heterologously expressed hNav1.7 sodium channels using the patch-clamp method and hypothesized that use-dependent sodium channel blockade contributes to the analgesic activity of (R)-31b and (S)-22b.
References
More filters
Journal ArticleDOI
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement
TL;DR: Moher et al. as mentioned in this paper introduce PRISMA, an update of the QUOROM guidelines for reporting systematic reviews and meta-analyses, which is used in this paper.
Journal Article
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
TL;DR: The QUOROM Statement (QUality Of Reporting Of Meta-analyses) as mentioned in this paper was developed to address the suboptimal reporting of systematic reviews and meta-analysis of randomized controlled trials.
Journal ArticleDOI
Bias in meta-analysis detected by a simple, graphical test
TL;DR: Funnel plots, plots of the trials' effect estimates against sample size, are skewed and asymmetrical in the presence of publication bias and other biases Funnel plot asymmetry, measured by regression analysis, predicts discordance of results when meta-analyses are compared with single large trials.
Journal ArticleDOI
Assessing the quality of reports of randomized clinical trials : is blinding necessary?
Alejandro R. Jadad,R. A. Moore,Dawn Carroll,C. Jenkinson,David Reynolds,David J. Gavaghan,Henry J McQuay +6 more
TL;DR: An instrument to assess the quality of reports of randomized clinical trials (RCTs) in pain research is described and its use to determine the effect of rater blinding on the assessments of quality is described.
Journal ArticleDOI
GRADE: an emerging consensus on rating quality of evidence and strength of recommendations
Gordon H. Guyatt,Andrew D Oxman,Gunn Elisabeth Vist,Regina Kunz,Yngve Falck-Ytter,Pablo Alonso-Coello,Holger J. Schünemann +6 more
TL;DR: The advantages of the GRADE system are explored, which is increasingly being adopted by organisations worldwide and which is often praised for its high level of consistency.